Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples